相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。HER2 Testing in Gastric Cancer
Luca Albarello et al.
ADVANCES IN ANATOMIC PATHOLOGY (2011)
Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer - A randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO)
Peter C. Thuss-Patience et al.
EUROPEAN JOURNAL OF CANCER (2011)
An open-label, multicentre biomarker-oriented AIO phase II trial of sunitinib for patients with chemo-refractory advanced gastric cancer
M. Moehler et al.
EUROPEAN JOURNAL OF CANCER (2011)
Palliative radiotherapy for bleeding from advanced gastric cancer: is a schedule of 30 Gy in 10 fractions adequate?
Hirofumi Asakura et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2011)
Pilot Induction Regimen Incorporating Pharmacokinetically Guided Topotecan for Treatment of Newly Diagnosed High-Risk Neuroblastoma: A Children's Oncology Group Study
Julie R. Park et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Epidermal growth factor receptor mutation in gastric cancer
Zhimin Liu et al.
PATHOLOGY (2011)
Ramucirumab (IMC-1121B): Monoclonal Antibody Inhibition of Vascular Endothelial Growth Factor Receptor-2
Jennifer Spratlin
CURRENT ONCOLOGY REPORTS (2011)
Randomised, non-comparative phase II study of weekly docetaxel with cisplatin and 5-fluorouracil or with capecitabine in oesophagogastric cancer: the AGITG ATTAX trial
N. C. Tebbutt et al.
BRITISH JOURNAL OF CANCER (2010)
Advanced gastric cancer - Slow but steady progress
Derek G. Power et al.
CANCER TREATMENT REVIEWS (2010)
A randomised phase II study of combination chemotherapy with epirubicin, cisplatin and capecitabine (ECX) or cisplatin and capecitabine (CX) in advanced gastric cancer
Jina Yun et al.
EUROPEAN JOURNAL OF CANCER (2010)
Randomized phase II study of sequential docetaxel and irinotecan with 5-fluorouracil/folinic acid (leucovorin) in patients with advanced gastric cancer: the GATAC trial
Michael Gubanski et al.
GASTRIC CANCER (2010)
HER-2 amplification is highly homogenous in gastric cancer
Michael Bilous et al.
HUMAN PATHOLOGY (2010)
CONSIDERATION OF THE ROLE OF RADIOTHERAPY FOR ABDOMINAL LYMPH NODE METASTASES IN PATIENTS WITH RECURRENT GASTRIC CANCER
Jing Sun et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2010)
Pyridoxine Is Not Effective to Prevent Hand-Foot Syndrome Associated With Capecitabine Therapy: Results of a Randomized, Double-Blind, Placebo-Controlled Study
Yoon-Koo Kang et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Phase II Study of Sorafenib in Combination With Docetaxel and Cisplatin in the Treatment of Metastatic or Advanced Gastric and Gastroesophageal Junction Adenocarcinoma: ECOG 5203
Weijing Sun et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Multicenter Phase II Study of Everolimus in Patients With Previously Treated Metastatic Gastric Cancer
Toshihiko Doi et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
Yung-Jue Bang et al.
LANCET (2010)
Population-based differences in treatment outcome following anticancer drug therapies
Brigette B. Y. Ma et al.
LANCET ONCOLOGY (2010)
Early Palliative Care for Patients with Metastatic Non-Small-Cell Lung Cancer
Jennifer S. Temel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Outcomes of Modified FOLFOX-6 as First Line Treatment in Patients with Advanced Gastric Cancer in a Single Institution; Retrospective Analysis
Han Hong Lee et al.
CANCER RESEARCH AND TREATMENT (2010)
Meta-analysis of the REAL-2 and ML17032 trials: evaluating capecitabine-based combination chemotherapy and infused 5-fluorouracil-based combination chemotherapy for the treatment of advanced oesophago-gastric cancer
A. F. C. Okines et al.
ANNALS OF ONCOLOGY (2009)
Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial
Y. -K. Kang et al.
ANNALS OF ONCOLOGY (2009)
Phase II study of cetuximab in combination with cisplatin and docetaxel in patients with untreated advanced gastric or gastro-oesophageal junction adenocarcinoma (DOCETUX study)
C. Pinto et al.
BRITISH JOURNAL OF CANCER (2009)
Palliative radiation therapy for hemorrhage of unresectable gastric cancer: a single institute experience
Kenji Hashimoto et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2009)
Is there a role for second-line chemotherapy in advanced gastric cancer?
Robert Wesolowski et al.
LANCET ONCOLOGY (2009)
Clinical benefit of palliative radiation therapy in advanced gastric cancer
Michelle M. Kim et al.
ACTA ONCOLOGICA (2008)
HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target
C. Gravalos et al.
ANNALS OF ONCOLOGY (2008)
Second-line chemotherapy for patients with advanced gastric cancer: who may benefit?
V. Catalano et al.
BRITISH JOURNAL OF CANCER (2008)
A phase II study of irinotecan and docetaxel combination chemotherapy for patients with previously treated metastatic or recurrent advanced gastric cancer
Sun Jin Sym et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2008)
Tumor lysis syndrome after capecitabine plus cisplatin treatment in advanced gastric cancer
Hye-Suk Han et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Potential regional differences for the tolerability profiles of fluoropyrimidines
Daniel G. Haller et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin:: A study of the arbeitsgemeinschaft internistische onkologie
Salah-Eddin Al-Batran et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial
Wasaburo Koizumi et al.
LANCET ONCOLOGY (2008)
Capecitabine and oxaliplatin for advanced esophagogastric cancer
David Cunningham et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
A phase II study of docetaxel as salvage chemotherapy in advanced gastric cancer after failure of fluoropyrimidine and platinum combination chemotherapy
Jae-Lyun Lee et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2008)
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine
Shinichi Sakuramoto et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Effect of gastrectomy on the pharmacokinetics of S-1, an oral fluoropyrimidine, in resectable gastric cancer patients
Mitsugu Kochi et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2007)
A phase II study of gefitinib monotherapy in advanced Esophageal adenocarcinoma: Evidence of gene expression, cellular, and clinical response
David R. Ferry et al.
CLINICAL CANCER RESEARCH (2007)
Phase II study of cetuximab in combination with FOLFIRI in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma (FOLCETUX study)
C. Pinto et al.
ANNALS OF ONCOLOGY (2007)
The role of palliative radiation therapy in symptomatic locally advanced gastric cancer
Jeremy Tey et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2007)
Value of high-cost cancer care: A behavioral science perspective
Kevin P. Weinfurt
JOURNAL OF CLINICAL ONCOLOGY (2007)
Multicenter phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinorna
Manish A. Shah et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: A report of the V325 study group
Eric Van Cutsem et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Phase II trial of erlotinib in gastroesophageal junction and gastric adenocarcinomas: SWOG 0127
Tomislav Dragovich et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer
David Cunningham et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Predictive factors for outcome in a phase II study of gefitinib in second-line treatment of advanced esophageal cancer patients
ML Janmaat et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Epidemiology of gastric cancer
Katherine D. Crew et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2006)
A phase II study of biweekly oxaliplatin plus infusional 5-fluorouracil and folinic acid (FOLFOX-4) as first-line treatment of advanced gastric cancer patients
F De Vita et al.
BRITISH JOURNAL OF CANCER (2005)
Association between expression of transcription factor Sp1 and increased vascular endothelial growth factor expression, advanced stage, and poor survival in patients with resected gastric cancer
JC Yao et al.
CLINICAL CANCER RESEARCH (2004)
p53 and VEGF expression are independent predictors of tumour recurrence and survival following curative resection of gastric cancer
C Fondevila et al.
BRITISH JOURNAL OF CANCER (2004)
Phase II study of irinotecan and 5-fluorouracil/leucovorin in patients with primary refractory or relapsed advanced oesophageal and gastric carcinoma
L Assersohn et al.
ANNALS OF ONCOLOGY (2004)
Weekly irinotecan in patients with metastatic gastric cancer failing cisplatin-based chemotherapy
JH Chun et al.
JAPANESE JOURNAL OF CLINICAL ONCOLOGY (2004)
A multicentre, randomised phase III trial comparing protracted venous infusion (PVI) 5-fluorouracil (5-FU) with PVI5-FU plus mitomycin C in patients with inoperable oesophago-gastric cancer
NC Tebbutt et al.
ANNALS OF ONCOLOGY (2002)
Prospective randomized trial comparing mitomycin, cisplatin, and protracted venous-infusion fluorouracil (PV1 5-FU) with epirubicin, cisplatin, and PV15-FU in advanced esophagogastric cancer
P Ross et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction.
JS Macdonald et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
分享论文
